Author

Gerassimos J. Mantzaris

Joint manifestations and their effect on treatment options
Joint manifestations and their effect on treatment options

Gerassimos J. Mantzaris

THE NATURAL HISTORY OF COVID-19 IN VACCINATED INFLAMMATORY BOWEL DISEASE PATIENTS
THE NATURAL HISTORY OF COVID-19 IN VACCINATED INFLAMMATORY BOWEL DISEASE PATIENTS

TOFACITINIBFOR THETREATMENT OFMODERATE - SEVERE ULCERATIVE COLITIS. THE GREEK EXPERIENCE
TOFACITINIBFOR THETREATMENT OFMODERATE - SEVERE ULCERATIVE COLITIS. THE GREEK EXPERIENCE

SIMPLIFIED RULES TO IDENTIFY BIO-NAÏVE PATIENTS WITH CROHN'S DISEASE WITH HIGHER LIKELIHOOD OF CLINICAL REMISSION WHEN INITIATING VEDOLIZUMAB VERSUS ANTI-TNF THERAPIES: ANALYSIS OF EVOLVE STUDY DATA
SIMPLIFIED RULES TO IDENTIFY BIO-NAÏVE PATIENTS WITH CROHN'S DISEASE WITH HIGHER LIKELIHOOD OF CLINICAL REMISSION WHEN INITIATING VEDOLIZUMAB VERSUS ANTI-TNF THERAPIES: ANALYSIS OF EVOLVE STUDY DATA

SIMPLIFIED RULES TO IDENTIFY BIO-NAÏVE PATIENTS WITH CROHN’S DISEASE WITH HIGHER LIKELIHOOD OF CLINICAL REMISSION WHEN INITIATING VEDOLIZUMAB VERSUS ANTI-TNF THERAPIES: ANALYSIS OF EVOLVE STUDY DATA
SIMPLIFIED RULES TO IDENTIFY BIO-NAÏVE PATIENTS WITH CROHN’S DISEASE WITH HIGHER LIKELIHOOD OF CLINICAL REMISSION WHEN INITIATING VEDOLIZUMAB VERSUS ANTI-TNF THERAPIES: ANALYSIS OF EVOLVE STUDY DATA

Gerassimos J. Mantzaris  et al.

TWELVE-MONTH OUTCOMES OF TREATMENT WITH USTEKINUMAB IN PATIENTS WITH CROHN’S DISEASE, IN A REAL-LIFE SETTING IN GREECE: INTERIM ANALYSIS OF THE ‘REASSURE’ STUDY
TWELVE-MONTH OUTCOMES OF TREATMENT WITH USTEKINUMAB IN PATIENTS WITH CROHN’S DISEASE, IN A REAL-LIFE SETTING IN GREECE: INTERIM ANALYSIS OF THE ‘REASSURE’ STUDY

Gerassimos J. Mantzaris  et al.

AN ELUSIVE MANIFESTATION OF COVID-19: DYSPHAGIA DUE TO ESOPHAGO-GASTRIC JUNCTION DISORDERS
AN ELUSIVE MANIFESTATION OF COVID-19: DYSPHAGIA DUE TO ESOPHAGO-GASTRIC JUNCTION DISORDERS

Gerassimos J. Mantzaris  et al.

EFFECTS OF COVID-19 ON EMPLOYMENT IN IBD PATIENTS
EFFECTS OF COVID-19 ON EMPLOYMENT IN IBD PATIENTS

Gerassimos J. Mantzaris  et al.

MENTAL HEALTH, WORK PRESENTEEISM AND EXERCISE IN IBD PATIENTS
MENTAL HEALTH, WORK PRESENTEEISM AND EXERCISE IN IBD PATIENTS

Gerassimos J. Mantzaris  et al.

European Crohn’s and Colitis Organisation Topical Review on Environmental Factors in IBD
European Crohn’s and Colitis Organisation Topical Review on Environmental Factors in IBD

Gerassimos J. Mantzaris  et al.

LEADING FACTORS OF LIVER INJURY AMONG HOSPITALIZED PATIENTS WITH COVID-19: EXPERIENCE FROM A COVID-19 REFERRAL HOSPITAL
LEADING FACTORS OF LIVER INJURY AMONG HOSPITALIZED PATIENTS WITH COVID-19: EXPERIENCE FROM A COVID-19 REFERRAL HOSPITAL

Gerassimos J. Mantzaris  et al.

THE INFLAMMATORY BOWEL DISEASE – DISK TOOL FOR ASSESSING DISABILITY IN INFLAMMATORY BOWEL DISEASE PATIENTS: VALIDATION OF THE GREEK VERSION
THE INFLAMMATORY BOWEL DISEASE – DISK TOOL FOR ASSESSING DISABILITY IN INFLAMMATORY BOWEL DISEASE PATIENTS: VALIDATION OF THE GREEK VERSION

Gerassimos J. Mantzaris  et al.

PREGNANCY OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RETROSPECTIVE DATA FROM A GREEK NATIONAL REGISTRY
PREGNANCY OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RETROSPECTIVE DATA FROM A GREEK NATIONAL REGISTRY

Gerassimos J. Mantzaris  et al.

SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN IBD IN CLINICAL REMISSION IS ASSOCIATED WITH A LOWER RATE OF DRUG DISCONTINUATION, DRUG OPTIMIZATION, AND REVERSE-SWITCH: AN INTERNATIONAL MULTICENTER STUDY
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN IBD IN CLINICAL REMISSION IS ASSOCIATED WITH A LOWER RATE OF DRUG DISCONTINUATION, DRUG OPTIMIZATION, AND REVERSE-SWITCH: AN INTERNATIONAL MULTICENTER STUDY

Gerassimos J. Mantzaris  et al.

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management

Gerassimos J. Mantzaris  et al.

TOFACITINIBFOR THETREATMENT OFMODERATE - SEVERE ULCERATIVE COLITIS. THE GREEK EXPERIENCE
TOFACITINIBFOR THETREATMENT OFMODERATE - SEVERE ULCERATIVE COLITIS. THE GREEK EXPERIENCE

Gerassimos J. Mantzaris  et al.

PRELIMINARY DATA ON THE EFFICACY OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS IN A 'REAL-WORLD' CLINICAL SETTING
PRELIMINARY DATA ON THE EFFICACY OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS IN A 'REAL-WORLD' CLINICAL SETTING

Gerassimos J. Mantzaris  et al.

“REAL WORLD” PRELIMINARY DATA ON THE EFFICACY AND SAFETY OF 16-WEEK INDUCTION THERAPY WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS
“REAL WORLD” PRELIMINARY DATA ON THE EFFICACY AND SAFETY OF 16-WEEK INDUCTION THERAPY WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS

Gerassimos J. Mantzaris  et al.

THE NATURAL HISTORY OF COVID-19 IN VACCINATED INFLAMMATORY BOWEL DISEASE PATIENTS
THE NATURAL HISTORY OF COVID-19 IN VACCINATED INFLAMMATORY BOWEL DISEASE PATIENTS

Gerassimos J. Mantzaris  et al.

THIRD-LINE THERAPY IN REFRACTORY ULCERATIVE COLITIS: A COMPARISON BETWEEN TOFACITINIB AND USTEKINUMAB
THIRD-LINE THERAPY IN REFRACTORY ULCERATIVE COLITIS: A COMPARISON BETWEEN TOFACITINIB AND USTEKINUMAB

Gerassimos J. Mantzaris  et al.

Item 1 - 20 / 23
1
2